MA40871A - Expression directe d'anticorps - Google Patents
Expression directe d'anticorpsInfo
- Publication number
- MA40871A MA40871A MA040871A MA40871A MA40871A MA 40871 A MA40871 A MA 40871A MA 040871 A MA040871 A MA 040871A MA 40871 A MA40871 A MA 40871A MA 40871 A MA40871 A MA 40871A
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- direct expression
- expression
- direct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32041—Use of virus, viral particle or viral elements as a vector
- C12N2770/32043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14190943 | 2014-10-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA40871A true MA40871A (fr) | 2017-09-05 |
Family
ID=51844553
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA040871A MA40871A (fr) | 2014-10-29 | 2015-10-27 | Expression directe d'anticorps |
MA049781A MA49781A (fr) | 2014-10-29 | 2015-10-28 | Expression directe d'anticorps |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA049781A MA49781A (fr) | 2014-10-29 | 2015-10-28 | Expression directe d'anticorps |
Country Status (4)
Country | Link |
---|---|
US (1) | US20170313765A1 (fr) |
EP (2) | EP3663315A1 (fr) |
MA (2) | MA40871A (fr) |
WO (1) | WO2016066708A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
WO2018027184A1 (fr) * | 2016-08-05 | 2018-02-08 | Silarus Therapeutics, Inc. | Compositions d'anticorps spécifiques d'erfe et procédés d'utilisation |
WO2018031400A1 (fr) * | 2016-08-12 | 2018-02-15 | Janssen Biotech, Inc. | Anticorps de membres de la superfamille anti-tnfr modifiés par fc ayant une activité agoniste améliorée et leurs procédés d'utilisation |
WO2018232355A1 (fr) * | 2017-06-15 | 2018-12-20 | Modernatx, Inc. | Anticorps d'arn |
CN111836644B (zh) * | 2018-03-08 | 2024-07-23 | 凡恩世制药(北京)有限公司 | 抗密蛋白18.2抗体及其用途 |
US20210363543A1 (en) * | 2018-10-30 | 2021-11-25 | Nantbio, Inc. | Self Replicating RNA System |
CN113423729A (zh) * | 2018-11-06 | 2021-09-21 | 迈阿密大学 | 能够在体内进行糖工程化的重组aav病毒载体的组合物和产生 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4186745A (en) | 1976-07-30 | 1980-02-05 | Kauzlarich James J | Porous catheters |
US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
US6048729A (en) | 1987-05-01 | 2000-04-11 | Transkaryotic Therapies, Inc. | In vivo protein production and delivery system for gene therapy |
US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
US5674192A (en) | 1990-12-28 | 1997-10-07 | Boston Scientific Corporation | Drug delivery |
PT101031B (pt) | 1991-11-05 | 2002-07-31 | Transkaryotic Therapies Inc | Processo para o fornecimento de proteinas por terapia genetica |
US5733761A (en) | 1991-11-05 | 1998-03-31 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US6054288A (en) | 1991-11-05 | 2000-04-25 | Transkaryotic Therapies, Inc. | In vivo protein production and delivery system for gene therapy |
US5397307A (en) | 1993-12-07 | 1995-03-14 | Schneider (Usa) Inc. | Drug delivery PTCA catheter and method for drug delivery |
JP3403233B2 (ja) | 1994-01-20 | 2003-05-06 | テルモ株式会社 | バルーンカテーテル |
US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
WO1999016500A2 (fr) | 1997-10-01 | 1999-04-08 | Medtronic Ave, Inc. | Systeme de delivrance de medicament et de therapie genique |
DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
CA2766907A1 (fr) | 2009-07-06 | 2011-01-13 | Novartis Ag | Molecules d'arn autorepliquantes et leurs utilisations |
MX350198B (es) * | 2011-07-06 | 2017-08-30 | Novartis Ag | Emulsiones aceite en agua que contienen acidos nucleicos. |
WO2013013013A2 (fr) | 2011-07-21 | 2013-01-24 | Alnylam Pharmaceuticals, Inc. | Compositions et procédés de production de glycoprotéines modifiées |
BR112015022855A2 (pt) | 2013-03-14 | 2017-11-07 | Shire Human Genetic Therapies | composições e método para produção de um anticorpo in vitro |
-
2015
- 2015-10-27 MA MA040871A patent/MA40871A/fr unknown
- 2015-10-28 US US15/520,510 patent/US20170313765A1/en not_active Abandoned
- 2015-10-28 EP EP20153125.8A patent/EP3663315A1/fr not_active Withdrawn
- 2015-10-28 WO PCT/EP2015/075027 patent/WO2016066708A1/fr active Application Filing
- 2015-10-28 EP EP15797871.9A patent/EP3212224A1/fr not_active Ceased
- 2015-10-28 MA MA049781A patent/MA49781A/fr unknown
Also Published As
Publication number | Publication date |
---|---|
WO2016066708A1 (fr) | 2016-05-06 |
MA49781A (fr) | 2021-06-02 |
EP3212224A1 (fr) | 2017-09-06 |
US20170313765A1 (en) | 2017-11-02 |
EP3663315A1 (fr) | 2020-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA42924A (fr) | Variants optimisés d'anticorps anti-vegf | |
FR24C1022I1 (fr) | Modulation d'activité du complément | |
MA42925A (fr) | Anticorps anti-tigit et méthodes d'utilisation | |
KR102355950B9 (ko) | Tigit에 대한 항체 | |
MA45004A (fr) | Anticorps spécifiques anti-wt1-hla | |
MA49726A (fr) | Formulation d'anticorps anti-cgrp | |
MA46057A (fr) | Anticorps anti-ctla4 | |
MA47472A (fr) | Anticorps | |
MA53297A (fr) | Anticorps anti-icos | |
CL2016001879A1 (es) | Anticuerpos humanos a pd-l1 | |
MA44381A (fr) | Format d'anticorps hétérodimères multispécifiques | |
MA51552A (fr) | Anticorps anti-ox40 et procédés d'utilisation | |
MA50352A (fr) | Anticorps multispécifiques | |
MA46180A (fr) | Analogues de l'amyline | |
MA49781A (fr) | Expression directe d'anticorps | |
MA44236A (fr) | Anticorps anti-tgfbêta 2 | |
FR3019522B1 (fr) | Ensemble sustentateur amovible d'un giravion et giravion | |
MA42843A (fr) | Anticorps anti-cd115 | |
MA51554A (fr) | Anticorps il-6 améliorés | |
FR3022462B1 (fr) | Composition orale d'anticorps anti-tnfalpha | |
KR20180085008A (ko) | 항-pcsk9 항체 및 그의 용도 | |
MA42690A (fr) | Micropropagation d'un dattier abada | |
MA40512A (fr) | Anticorps de l'angiopoïétine-like 4 et procédés d'utilisation correspondants | |
MA50654A (fr) | Anticorps anti-pacap | |
MA49257A (fr) | Anticorps anti-trkb |